S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
NASDAQ:PLXP

PLx Pharma Stock Forecast, Price & News

$9.96
+0.50 (+5.29%)
(As of 12/8/2021 04:00 PM ET)
Add
Compare
Today's Range
$9.29
$10.31
50-Day Range
$8.21
$20.77
52-Week Range
$5.01
$21.50
Volume
275,779 shs
Average Volume
395,238 shs
Market Capitalization
$274.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
4.49
30 days | 90 days | 365 days | Advanced Chart
Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.


PLx Pharma logo

About PLx Pharma

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Headlines

Raymond James Upgrades PLx Pharma (NASDAQ:PLXP) to "Outperform"
December 7, 2021 |  americanbankingnews.com
PLx Pharma Inc. (NASDAQ:PLXP) Short Interest Up 24.4% in October
November 21, 2021 |  americanbankingnews.com
PLx Pharma Inc. (PLXP)
November 13, 2021 |  ca.finance.yahoo.com
PLx Pharma Inc. Provides VAZALORE Launch Update
October 29, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLXP
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
$30 thousand
Book Value
$1.12 per share

Profitability

Net Income
$-15.21 million
Pretax Margin
-871.66%

Debt

Price-To-Earnings

Miscellaneous

Free Float
25,538,000
Market Cap
$274.27 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/11/2022

MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

1080th out of 1,394 stocks

Pharmaceutical Preparations Industry

511th out of 674 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

Is PLx Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma
or view top-rated stocks.

How has PLx Pharma's stock price been impacted by COVID-19?

PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PLXP stock has increased by 107.1% and is now trading at $9.96.
View which stocks have been most impacted by COVID-19
.

Are investors shorting PLx Pharma?

PLx Pharma saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 2,650,000 shares, an increase of 24.4% from the October 14th total of 2,130,000 shares. Based on an average daily trading volume, of 433,200 shares, the days-to-cover ratio is currently 6.1 days.
View PLx Pharma's Short Interest
.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, March 11th 2022.
View our earnings forecast for PLx Pharma
.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to the consensus estimate of $4.10 million. PLx Pharma's revenue for the quarter was up 560.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) EPS.
View PLx Pharma's earnings history
.

What price target have analysts set for PLXP?

4 brokers have issued 1 year target prices for PLx Pharma's stock. Their forecasts range from $14.00 to $29.00. On average, they anticipate PLx Pharma's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 115.9% from the stock's current price.
View analysts' price targets for PLx Pharma
or view top-rated stocks among Wall Street analysts.

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the following people:
  • Natasha Giordano, President, Chief Executive Officer & Director
  • Rita M. O'Connor, CFO, Head-Manufacturing & Supply Chain
  • Thomas L. Long, VP-Manufacturing & Technical Operations
  • Steven Valentino, Vice President-Trade Sales
  • Joanne Cotignola, Vice President-Marketing

What other stocks do shareholders of PLx Pharma own?

When did PLx Pharma IPO?

(PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Two Sigma Advisers LP (1.41%), EAM Investors LLC (1.36%), Two Sigma Investments LP (1.19%), BlackRock Inc. (1.04%), Geode Capital Management LLC (0.79%) and First Republic Investment Management Inc. (0.78%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino and Rita M O'connor.
View institutional ownership trends for PLx Pharma
.

Which institutional investors are selling PLx Pharma stock?

PLXP stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, and Heritage Way Advisors LLC.
View insider buying and selling activity for PLx Pharma
or view top insider-selling stocks.

Which institutional investors are buying PLx Pharma stock?

PLXP stock was bought by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., BlackRock Inc., Two Sigma Investments LP, Morgan Stanley, Two Sigma Advisers LP, EAM Investors LLC, O Brien Greene & Co. Inc, and Bank of New York Mellon Corp. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma
or or view top insider-buying stocks.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $9.96.

How much money does PLx Pharma make?

PLx Pharma has a market capitalization of $274.27 million and generates $30 thousand in revenue each year. The biotechnology company earns $-15.21 million in net income (profit) each year or ($3.19) on an earnings per share basis.

How many employees does PLx Pharma have?

PLx Pharma employs 10 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is www.plxpharma.com.

Where are PLx Pharma's headquarters?

PLx Pharma is headquartered at 9 Fishers Lane Suite E, Sparta NJ, 07871.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at (973) 409-6541, via email at [email protected], or via fax at 713-842-3052.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.